To obtain an overview of the responsiveness of GBM cells to human recombinant TRAIL, to IAP antagonist TL32711 or the combination thereof, we studied a panel of six commercially available or early passage GBM cell lines. The gene discussed is TNFSF10; the disease is glioblastoma.